EU/3/19/2213

Table of contents

About

On 17 October 2019, orphan designation EU/3/19/2213 was granted by the European Commission to Ascendis Pharma Endocrinology Division A/S, Denmark, for lonapegsomatropin for the treatment of growth hormone deficiency.

Key facts

Active substance
lonapegsomatropin
Disease / condition
Treatment of growth hormone deficiency
Date of first decision
17/10/2019
Outcome
Positive
EU designation number
EU/3/19/2213

Sponsor's contact details

Ascendis Pharma Endocrinology Division A/S
Tuborg Boulevard 5
2900 Hellerup 
Hovedstaden
Denmark
Tel: +45 70 22 22 44
E-mail: info@ascendispharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating